G1 Therapeuticslogo.JPG
G1 Therapeutics to Participate in the 40th Annual J.P. Morgan and H.C. Wainwright BioConnect Virtual Conferences in January 2022
January 04, 2022 09:15 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two...
G1 Therapeuticslogo.JPG
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2022 17:30 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1 Therapeuticslogo.JPG
G1 Therapeutics Announces Expansion of COSELA™ (Trilaciclib) Sales Force
December 16, 2021 06:00 ET | G1 Therapeutics
- G1 and Boehringer Ingelheim Mutually Agree to End Co-Promotion Agreement - - Management to Host Webcast and Conference Call today at 8:30 AM ET - RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2021 ...
G1 Therapeuticslogo.JPG
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2021 18:20 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1 Therapeuticslogo.JPG
G1 Therapeutics Initiates Phase 2 Trial to Support the Antitumor Mechanism of Action (MOA) of Trilaciclib in the Tumor Microenvironment
December 01, 2021 07:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has initiated a Phase 2,...
G1 Therapeuticslogo.JPG
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)
November 29, 2021 07:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has initiated a Phase 2,...
G1 Therapeuticslogo.JPG
Immune Analysis from Phase 2 Triple Negative Breast Cancer Trial Demonstrates Trilaciclib Enhanced Patients’ T Cell Immune Function When Administered Prior to Chemotherapy
November 12, 2021 08:25 ET | G1 Therapeutics
- Exploratory Analysis Investigated Immune Mechanisms Underlying The Significant Improvement In Overall Survival Shown In The Phase 2 TNBC Trial, Results Of Which Were Presented At 2020 San Antonio...
G1 Therapeuticslogo.JPG
G1 Therapeutics to Participate in Two Upcoming Conferences
November 10, 2021 11:40 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two...
G1 Therapeuticslogo.JPG
G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights
November 03, 2021 06:30 ET | G1 Therapeutics
- Achieved $4.9 Million in Total Revenue, Including $3.6 Million in Net Revenue from Sales of COSELA™ (trilaciclib) - - Announced Supplemental COSELA Sales Force to Target Top Tier Accounts and...
G1 Therapeuticslogo.JPG
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2021 18:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...